| Document |
Document Title |
|
WO/2009/065059A9 |
|
|
WO/2009/094845A1 |
5-(3-heteroaromatic ring substituted phenyl) tetrazole compounds of formula (I), pharmaceutically acceptable salts thereof, wherein the substituents are defined as same as claims. Preparation methods thereof, pharmaceutical compositions ...
|
|
WO/2009/094242A1 |
A compound having the structure (I) wherein R is an angiotensin receptor antagonist active group, Y is selected from the group consisting of (II), and 2) -C(R1H)OC(O)X((CR12R13)-(CHR10)m-(CH2)n-Zp-(CH2)q-(CHR11)r-(
CR16R17))-R5; Z is O- ...
|
|
WO/2009/090903A1 |
A novel platinum (II) binuclear complex compound capable of binding to DNA in a manner different from cisplatin preparations, a method of producing this compound, and an anticancer agent containing this compound as the active ingredient ...
|
|
WO/2009/089022A1 |
The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for det...
|
|
WO/2009/086753A1 |
Preparation methods of aminomethyl biphenyl tetrazole compounds of formula I or their salts and salts of formula II comprise that intermediates of formula III are reduced by reducing agents in an inert organic solvent to obtain aminometh...
|
|
WO/2009/077371A1 |
Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3,...
|
|
WO/2009/075080A1 |
Disclosed is a fluoroalkylsulfide derivative having excellent pest control activity or a salt thereof. Also disclosed is a pest control agent characterized by containing such a fluoroalkylsulfide derivative or a salt thereof as an active...
|
|
WO/2009/076173A2 |
The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ( I ) which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A prote...
|
|
WO/2009/069833A1 |
A core of a cyclic structure represented by (-N-(CH2)n-)k is bonded to a dendrimer-type side chain with a specific branched structure at all nitrogen atoms in the core to produce a compound with a specific structure for producing a metal...
|
|
WO/2009/068509A1 |
This invention relates to novel benzamide derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive ...
|
|
WO/2009/068557A1 |
This invention relates to novel phenyl-acetamide and phenyl- propionamide derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as divers...
|
|
WO/2009/065850A1 |
This invention relates to N-acylhydrazone derivatives, which are found to be useful as modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatme...
|
|
WO/2009/065081A2 |
A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular ...
|
|
WO/2009/065070A2 |
A prostaglandin analog with selectivity to EP receptors and demonstrating EP agonist activity that may be used to expand hematopoietic stem cell populations or to treat or prevent influenza, bone fracture, bone disease, glaucoma, ocular ...
|
|
WO/2009/061681A2 |
Described herein are compounds and pharmaceutical compositions containing such compounds that modulate the PGD2 activated chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2). Also described herein are methods of u...
|
|
WO/2009/056582A1 |
A compound of formula (I) or salts thereof, wherein R1, R2, R3, R4, n and X are as defined in the specification; a process for preparing such compounds, a pharmaceutical composition comprising such compounds; and the use of such compound...
|
|
WO/2009/054479A1 |
Disclosed is a spiro-ring compound represented by the general formula [Ia], a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt thereof.
|
|
WO/2009/052078A1 |
The invention relates to a compound of formula (I) or a tautomer thereof or a pharmaceutically acceptable salt thereof, wherein R1 to R11, W, X, Y, Z, and n are as defined herein. The invention also relates to methods of using the compou...
|
|
WO/2009/049305A2 |
The present invention provides tetrazole compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising the tetrazole compounds. The present invention provides metho...
|
|
WO/2009/043780A1 |
Compounds of the formula (I) wherein R1, R2, Ar1, Ar2, and n are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.
|
|
WO/2009/035543A1 |
The invention relates to compounds having the formula: (I) wherein: Ar, r, R3, Z, X, and R5-7 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have AT1 receptor antagonist activity and n...
|
|
WO/2009/025914A2 |
Fluoroalkoxybenzamide compounds which selectively bind Sigma-2 receptors are disclosed. These compounds, when labelled with 18F, can be used as radiotracers for imaging of tumors by positron emission tomography (PET). In addition, these ...
|
|
WO/2009/001375A2 |
An improved process for the preparation of substantially pure valsartan employing suitable reagents such as chelating agent and reaction conditions.
|
|
WO/2008/157537A2 |
Disclosed herein are novel compositions and methods for treating or preventing a variety of disorders and conditions associated with lipid metabolism. The methods generally include administering to a patient in need thereof a therapeutic...
|
|
WO/2008/156142A1 |
It is intended to provide a novel compound which has AT2 receptor agonism and is capable of being expected as a pharmaceutical and to provide a therapeutic or preventive method for various diseases. A novel malonic acid sulfonamide deriv...
|
|
WO/2008/157162A1 |
Disclosed are novel dipeptide analogs compounds of Formula (I), (II) or (III) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, or a prodrug thereof, which are inhibitors of factor XIa and/or plasma kallikrein...
|
|
WO/2008/148599A2 |
The invention relates to a new salt of Valsartan, in particular to the high-purity dilithium salt of Valsartan, its polymorphs and solvates or hydrates thereof, useful for obtaining Valsartan with a high yield. The process for obtaining ...
|
|
WO/2008/143724A2 |
Lead-free primary explosives of the formula [MII(A)R(BX)S](CY)T, where A is 1,5-diaminotetrazole, and syntheses thereof are described. Substantially stoichiometric equivalents of the reactants lead to high yields of pure compositions the...
|
|
WO/2008/138871A1 |
The present invention relates to a process for preparing valsartan from a compound of general formula (I), wherein R is cumyl, trityl or t-butyl. The process comprises a first step, wherein the protective group is eliminated and thereaft...
|
|
WO/2008/139987A1 |
Disclosed is a novel aralkyl carboxylic acid compound which has an agonistic activity on GPR-120 and/or GPR-40, particularly GPR-120, and is therefore useful as an appetite regulator, an anti-obesity agent, a therapeutic agent for diabet...
|
|
WO/2008/135447A1 |
This invention relates to novel acetamide derivatives that are found to be potent modulators of ion channels, in particular potassium channels and chloride channels, and, as such, are valuable candidates for the treatment of diseases or ...
|
|
WO/2008/135448A1 |
This invention relates to novel β-keto-amide derivatives that are found to be potent modulators of ion channels, and in particular potassium channels and chloride channels, and, as such, are valuable candidates for the treatment of dise...
|
|
WO/2008/135762A1 |
An N-[(2'-(1-triphenyl methyl tetrazole-5-yl) biphenyl]-4-yl] methyl]-L-valine benzyl ester organic salt of formula (IVA) wherein A represents an organic carboxylic acid, a process for its preparation and its use in the synthesis of vals...
|
|
WO/2008/135591A1 |
This invention relates to novel benzamidine derivatives of formula (I) that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those whic...
|
|
WO/2008/131582A1 |
The method for making candixatan ester and intermediates thereof and a compound of formula III, wherein R1 is triphenylmethyl, methxoycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, benzoxycarbonyl, trimethylsilane, triethylsliane or trit...
|
|
WO2008087656B1 |
A process for the preparation of unsymmetrical biaryl compounds of Formula (I) wherein, R is alkyl, R' is cyano, protected or unprotected tetrazole, or Formula (a) wherein, R" is alkyl, aryl, aralkyl or alkoxy, said process comprising, r...
|
|
WO/2008/133288A1 |
Compounds represented by the general formula (1) or pharmacologically acceptable salts thereof; and squalene synthase inhibitors containing the same as the active ingredient: (1) (wherein R1 is phenyl which may be substituted with haloge...
|
|
WO/2008/129129A1 |
Fatty acid amide hydrolase inhibitors of the Formula (I) are provided, wherein R is a heterocyclic or heterocyclic carbonyl moiety and R' is a group consisting of H, substituted or unsubstituted alkyl, substituted or unsubstituted hetero...
|
|
WO/2008/131134A1 |
This application relates to certain novel polycyclic compounds that interact with quadruplex-forming regions of polynucleotides and thereby inhibit translation of genetic information into polypeptides. These compounds can thus provide an...
|
|
WO/2008/123207A1 |
[PROBLEMS] To provide a compound useful as a therapeutic agent for chronic renal failure or diabetic neuropathy. [MEANS FOR SOLVING PROBLEMS] Disclosed is an ornithine derivative having an EP4 receptor antagonistic activity. In the compo...
|
|
WO/2008/122787A1 |
The present invention relates to compounds of general formula (I): wherein A, Y, X, n and B are as defined herein; and their use in the treatment and prevention of metabolic disorders, inflammatory conditions, allergic conditions, fever,...
|
|
WO/2008/120992A1 |
The invention relates to the field of antibiotic compositions, both inside and outside the medical field. Presented is a new class of antibiotic compounds, variants of bis(l-aryl-5-tetrazolyl)methanes, which are especially useful for com...
|
|
WO/2008/119028A1 |
Alkenydiarylmethane compounds are described. Such compounds are a class of non-nucleoside inhibitors of HIV-I reverse transcriptase, which may also be used as part of a combination therapy to treat HIV infection. Compounds described here...
|
|
WO/2008/104994A2 |
Compounds of the present disclosure are 2,2,2-tri-substituted acetamide derivatives of formula (I), its polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts and formulations thereof, useful as Glucokinase acti...
|
|
WO/2008/105473A1 |
[PROBLEMS] To provide an anti-tumor agent which is excellent in the tumor accumulation property and the ability of reducing a tumor size. [MEANS FOR SOLVING PROBLEMS] Disclosed is an anti-tumor agent comprising a compound represented by ...
|
|
WO/2008/105505A1 |
Disclosed are a high-quality bis-(1(2)H-tetrazol-5-yl)amine compound and a method for safely producing the compound at low cost.Also disclosed are a reaction intermediate necessary for the production of the compound and a method for prod...
|
|
WO/2008/101665A1 |
The present application describes macrocyclic compounds of formula (I) with NS3 protease inhibitory activity for treating hepatitis C virus infection.
|
|
WO/2008/097459A2 |
The invention is directed to compounds of formula (I): wherein Ar, r, R3, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. The compounds of formula (I) have AT1 receptor antagonist activity ...
|
|
WO/2008/092120A1 |
The present invention provides a novel class of macrocyclic compounds as well as complexes formed between a metal (e.g., lanthanide) ion and the compounds of the invention. Preferred complexes exhibit high stability as well as high quant...
|
